Edizione	[1st ed. 2023.]
Pubbl/distr/stampa	Cham : , : Springer International Publishing : , : Imprint : Springer, , 2023
Descrizione fisica	1 online resource (vi, 171 pages) : illustrations (some color)
Disciplina	616.92 616.9041
Collana	Advances in Microbiology, Infectious Diseases and Public Health
Soggetto topico	Medical microbiology Biofilms Microbial populations Microbiology - Technique
ISBN	3-031-34178-3
Formato	Materiale a stampa
Livello bibliografico	Monografia
Lingua di pubblicazione	eng
Nota di contenuto	Chapter 1 Phytochemicals Against Drug-Resistant Bacterial Biofilms and Use of Green Extraction Solvents to Increase Their Bioactivity -- Chapter 2 In Vitro Potential Virucidal Effect Evaluation of Xibornol on Human Adenovirus Type 5, Human Rhinovirus Type 13, Human Coronavirus 229E, Human Parainfluenza Virus Type 1, and Human Respiratory Syncytial Virus -- Chapter 3 Man Who Won the War”: Myth and Reality of Aldo Castellani’s Rolein Preserving the Health of Troops During the Italo-Ethiopian War 1935–1936 -- Chapter 4 Biofilm associated infections in chronic wounds and their management -- Chapter 5 Relevance and importance of biofilms in the resistance and spreading of Campylobacter spp. within the food chain -- Chapter 6 Magnitude and Molecular Characterization of Extended-Spectrum β-Lactamase Genes among Klebsiella pneumoniae Isolates in a large Tertiary Hospital in Ethiopia -- Chapter 7 Seasonal variation analysis for weekly cases, deaths, and hospitalizations of COVID-19 in the United States of America -- Chapter 8 Trends of Antimicrobial Consumption in Hospital: Tackling the Hidden Part of the Iceberg with an Electronic Personalised Prescription Software for Antimicrobial Stewardship -- Chapter 9 Microbiota and Thyroid Disease: An Updated Systematic Review -- Chapter 10 Taxus wallichiana Zucc. (Himalayan Yew) a medicinal plant exhibiting antibacterial prope -- Chapter 11 Different efflux pump systems in Acinetobacter baumannii and their role in multidrug resistance -- Index.
Record Nr.	UNINA-9910728937603321

Edizione	[1st ed. 2022.]
Pubbl/distr/stampa	Cham : , : Springer International Publishing : , : Imprint : Springer, , 2022
Descrizione fisica	1 online resource (143 pages)
Disciplina	616.92
Collana	Advances in Microbiology, Infectious Diseases and Public Health
Soggetto topico	Medical microbiology Biofilms Microbial populations Microbiology - Technique Medical Microbiology Microbial Communities Microbiology Techniques Microbiologia mèdica Salut pública Malalties infeccioses
Soggetto genere / forma	Llibres electrònics
ISBN	9783031019951 9783031019944
Formato	Materiale a stampa
Livello bibliografico	Monografia
Lingua di pubblicazione	eng
Nota di contenuto	Personalized nutrition for microbiota correction and metabolism restore in type 2 diabetes mellitus patients -- Beyond Bone: Infectious diseases and immunity in parathyroid disorders -- In vitro antimicrobial susceptibility testing of biofilm-growing bacteria: current and emerging methods -- Antibiofilm Efficacy of Polihexanide, Octenidine and Sodium Hypochlorite/Hypochlorous Acid Based Wound Irrigation Solutions against Staphylococcus aureus, Pseudomonas aeruginosa and a Multispecies Biofilm -- Molecular Characterization of Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae Isolates Collected from Inanimate Hospital Environments in Addis Ababa, Ethiopia -- Distribution and Antibiotics Resistance Pattern of Community-Acquired Methicillin-Resistance Staphylococcus aureus in Southwestern Nigeria -- Ultrastructural and Immunohistochemical Diagnosis of a Neonatal Herpes Simplex Virus Infection Presenting as Fulminant Hepatitis: A Case Report -- Antimicrobial Activity of Xibornol and a Xibornol-Based Formulation Against Gram-Positive Pathogens of the Respiratory Tract -- Achille Sclavo (1861-1930) and his innovative contributions to Italian preventive medicine and healthcare policy -- The magnitude of Carbapenemase and ESBL producing Enterobacteriaceae isolates from patients with Urinary Tract Infections at Tikur Anbessa Specialized Teaching Hospital, Addis Ababa, Ethiopia.
Record Nr.	UNINA-9910568270403321

Pubbl/distr/stampa	Cham, Switzerland : , : Springer, , [2022]
Descrizione fisica	1 online resource (569 pages)
Disciplina	579.17
Collana	Springer Series on Biofilms
Soggetto topico	Biofilms
Soggetto genere / forma	Llibres electrònics
ISBN	3-031-10992-9
Formato	Materiale a stampa
Livello bibliografico	Monografia
Lingua di pubblicazione	eng
Nota di contenuto	Intro -- Preface -- Keywords -- Acknowledgments -- Contents -- About the Editors -- Part I: Introduction -- Introduction: Biofilms 101 -- 1 History of Biofilms -- 1.1 Biofilms Prevalence -- 1.2 How to Define a Biofilm -- 2 Physiology of a Biofilm -- 2.1 Matrix -- 2.1.1 Chemical Gradients in the Biofilm -- 3 Biofilm Implications in Infections -- 3.1 Antibiotic Tolerance and Resistance -- 3.1.1 Immune Evasion/Defense -- References -- Antimicrobial and Innate Immune Tolerance Mechanisms in Biofilms -- 1 Introduction -- 1.1 Antimicrobial Penetration -- 2 Reduced Envelope Permeability by Matrix Polysaccharides -- 2.1 Cell Physiological States -- 2.1.1 Dormancy and Slow Growth -- 2.1.2 Metabolic Adaptation -- 2.1.3 Stress Responses -- 2.2 Innate Immune Response -- 2.2.1 Early Growth and Establishment -- 2.2.2 Immune Evasion and Modulation -- 2.2.3 Virulence Factor Production -- 3 Conclusion -- References -- Antibiotic Resistance Development in Bacterial Biofilms -- 1 Introduction -- 2 Mechanisms of Tolerance to Antibiotics in Biofilms -- 2.1 Physical Tolerance -- 2.2 Physiological Tolerance -- 2.3 Persisters -- 2.4 Expression of Specific Genes -- 2.5 Adaptive Tolerance -- 2.6 In Vivo Tolerance -- 3 Antibiotic Resistance Development in Biofilms -- 3.1 Mutational Resistance -- 3.2 Horizontal Gene Transfer -- 3.3 Conclusion and Future Perspectives -- References -- Part II: Biofilm Prevention & -- Treatment -- Prevention of Biofilms in Catheter-Associated Urinary Tract Infections (CAUTIs): A Review -- 1 Introduction -- 2 Etiology of Catheter-Associated Urinary Tract Infection -- 2.1 Means of Infection -- 2.2 Organisms of Infection -- 3 Diagnosis of CAUTI -- 3.1 Clinical Guidelines and Symptoms -- 3.2 Role of Biofilms in CAUTI Diagnosis -- 4 Laboratory-Based Biofilm Quantification Methods -- 4.1 Culture -- 4.2 Sonication. 4.3 Microscopy for Visualization and Quantification -- 4.3.1 Scanning Electron Microscope -- 4.3.2 Atomic Force Microscopy -- 4.3.3 Confocal Fluorescence Microscopy -- 4.3.4 Image Software for Biofilm Quantification -- 5 Current and Future Prevention Strategies -- 5.1 Antimicrobial Coatings (Metals/Metal Oxides) -- 5.2 Hydrogel Coatings -- 5.3 Antibiotic Coatings -- 5.4 Enzyme Coatings -- 5.5 Surface Energy Coatings -- 5.6 Iron Scavenging Coatings -- 5.7 Methods to Test Antimicrobial Surfaces -- 6 Treatment Strategies -- 6.1 Proper Catheter Use and Monitoring -- 6.2 Antibiotic Treatment -- 7 Conclusions -- References -- Probiotics Action Against Biofilms -- 1 Introduction -- 2 Strategies for Fighting Against Bacterial Biofilm Infections -- 3 The Mechanisms of Action of Probiotics Against Biofilm-related Infections -- 3.1 Competition with Pathogenic Organisms for Adhesion and Nutrition -- 3.2 Secretion of Antimicrobial Substances -- 3.3 Impacting Intestinal Barrier Function -- 3.4 Immunomodulation -- 4 Role of Probiotics and their Derivatives in the Eradication of Biofilms -- 4.1 The Inhibition of Biofilm Formation by Probiotics -- 4.2 Probiotics Eradicate the Formed Biofilms -- 4.3 Probiotic Biofilms Against Pathogenic Biofilms -- 5 Clinical Applications of Probiotics -- 6 Conclusion and Future Perspectives -- References -- Clinical Translation of Biofilm Dispersal Agents -- 1 Introduction -- 2 Biofilm Dispersal -- 2.1 Active Biofilm Dispersal -- 2.1.1 Environmental Cues -- 2.1.2 Fatty Acid Signals -- 2.1.3 Peptide Signals -- 2.1.4 Nitric Oxide -- 2.1.5 Cyclic Dimeric GMP -- 2.1.6 Pseudomonas Quinolone Signal -- 2.1.7 Acyl-Homoserine Lactones -- 2.2 Passive Biofilm Dispersal -- 2.2.1 Proteases -- 2.2.2 DNases -- 2.2.3 Glycoside Hydrolases -- 3 Biofilm Dispersal Agents in the Pipeline -- 3.1 Small Molecule Modulators of Dispersion. 3.2 Modulators of c-di-GMP -- 3.3 Compounds Targeting the Protective Biofilm Matrix -- 3.4 Inhibiting the Function of Enzymes and Components Present in the Biofilm Matrix -- 3.5 Targeting the Outer Membrane -- 3.6 Essential Oils -- 4 Hurdles for Development -- 4.1 Regulatory Obstacles -- 4.2 Therapeutic Risks and Rewards -- 5 Conclusion and Future Perspectives -- References -- Chemical Regulation of Pseudomonas aeruginosa Biofilm Formation as a Potential Treatment for Persistent Infections -- 1 Introduction -- 2 Quorum Sensing -- 3 c-di-GMP Signalling -- 4 Chemical Modulation of Quorum Sensing and c-di-GMP Signalling -- 5 Quorum Sensing Inhibition -- 6 Interference with c-di-GMP Signalling -- 7 Conclusions and Perspectives -- References -- Bacteriophages for the Treatment of Biofilm-Associated Infections -- 1 Introduction -- 2 Biofilm Basics -- 3 Bacteriophage Basics -- 4 Phage-Biofilm Interactions -- 5 Overcoming the Limitations of Using Phages for Therapy -- 6 Phages in Action -- 7 Outlook -- References -- Hyperbaric Oxygen Treatment May Advance the Outcome of Antibiotic Treatment of Biofilm Infections -- 1 Introduction -- 2 Internal Microenvironment -- 3 External Microenvironment -- 4 Reversing Lack of O2 by HBOT Improves Treatment Outcome -- 5 Mimicking the Infectious Microenvironment Impacts Susceptibility Testing -- 6 Oxygen Therapy as an Adjunctive to Antibiotic Treatment of Bacterial Biofilms -- References -- Cold Plasma Therapy as a Physical Antibiofilm Approach -- 1 Introduction -- 2 Cold Plasma -- 3 Biofilm Destruction by Plasma -- 3.1 Biofilm Damage by Reactive Oxygen and Nitrogen Species (RONS) -- 3.2 Ultraviolet Radiation -- 3.3 Quorum Sensing Disruption -- 4 Plasma-Activated Liquids -- 4.1 Physicochemical Properties of Plasma-Activated Liquids -- 4.2 Antibiofilm Activity of Plasma-Activated Liquids. 5 Plasma and Plasma-Activated Liquid Cleaning and Coating of Medical Devices and Surfaces -- 6 Plasma Medicine in Dental Infections -- 6.1 Dental Caries -- 6.2 Root Canal Infections (E. faecalis) -- 6.3 Periodontal Disease Bacteria -- 6.4 C. albicans -- 7 Plasma Medicine in Dermatological Infections -- 7.1 Plasma Therapy in Wound Healing -- 8 Challenges to Biofilm Destruction by Cold Plasma -- 8.1 Plasma Tolerance -- 9 Conclusions and Future Perspectives -- References -- Antibodies Against Biofilms: Mechanisms and Applications -- 1 Introduction to Antibodies and B Cells -- 1.1 Antibody Structure and Functional Classification -- 1.2 Antibodies Are Naturally Produced by B Cells -- 1.3 Monoclonal Antibodies Can Be Produced Synthetically upon Request -- 2 Mechanisms of Antibody-Mediated Functions -- 2.1 Fab-Mediated Pathogen Blocking -- 2.2 Fc-Mediated Pathogen Blocking -- 3 Antibacterial Antibodies in the Clinic and Biotech -- 4 Antibodies as Weapons Against Biofilm -- 5 Anti-biofilm Antibodies Targeting Bacterial Cell Surface Associated Components -- 5.1 Antibodies Directed Against Other Cell-Associated Proteins -- 5.2 Antibodies Directed Against Cell-Associated Polysaccharides -- 6 Anti-biofilm Antibodies Targeting Secreted Bacterial Extracellular Components -- 6.1 Antibodies Directed Against DNA Binding Proteins -- 6.2 Antibodies Directed Against Exopolysaccharides -- 6.3 Antibodies Directed Against Extracellular Enzymes -- 6.4 Antibodies Directed to Toxins -- 7 Antibodies Against Fungi-Associated Biofilm -- 8 Conclusions -- References -- Host Defense Peptides: Multifront Attack on Biofilms -- 1 Introduction -- 2 Main Body -- 2.1 General Features and Terminology of Host Defense Peptides -- 2.2 HDPs Orchestrate Multifront Attacks on Biofilms -- 2.3 Diversity of HDP-Mediated Antibiofilm Activities -- 2.4 Regulatory Pathways Driving Biofilm Growth. 2.5 Biofilm-Specific Mechanisms of Action and Target Pathways of HDPs -- 2.5.1 Effects on the Stringent Response -- 2.5.2 Other Antibiofilm Mechanisms -- 2.6 Direct Antimicrobial Activity of HDPs -- 2.7 Immunomodulatory Mechanisms of HDPs Relevant for the Treatment of Biofilm Infections -- 3 Conclusion and Future Perspectives -- 4 Compliance with Ethical Standards -- References -- Learning from Nature: Naturally Derived Remedies -- 1 Introduction -- 2 Honey -- 2.1 Antibiofilm Properties of Honey -- 2.2 Clinical Application of Honey in Otolaryngology -- 2.2.1 Chronic Rhinosinusitis -- 2.2.2 Otologic Diseases -- 2.2.3 Radiation-induced Oral Mucositis -- 2.3 Diabetic Foot Ulcers and Chronic Wounds -- 2.4 Honey and Skin Disease -- 3 Essential Oils -- 4 Tea -- 5 Other Natural Products -- 6 Conclusion -- References -- Historical Medical Remedies as Potential Anti-Biofilm Approaches: Can We Look Back to Move Forward? -- 1 Introduction -- 2 Descriptions in Historical Texts of Common Infections Known to Be Associated with Biofilms -- 3 Evaluation of Historical Remedies for Infections Associated with Biofilms -- 4 Plant-Based Remedies with Anti-Biofilm Potential -- 5 Animal-Based Remedies with Anti-Biofilm Potential -- 6 Inanimate Material-Based Approaches with Anti-Biofilm Potential -- 7 Conclusions -- References -- Part III: Biofilm Control -- The Action of Phytochemicals in the Control of Pathogenic Biofilms -- 1 Introduction -- 2 Biofilm-Related Infections -- 2.1 Critical Multidrug-Resistant Pathogens -- 2.2 Biofilm Formation and Specific Mechanisms -- 3 Antibacterial Strategies Based on Natural Products to Target Biofilms -- 3.1 Targeting Bacterial Biofilms with Phytochemicals -- 3.1.1 Effects of Phytochemicals in QS Mechanisms -- 3.1.2 Effects of Phytochemicals on Motility -- 3.1.3 Effects of Phytochemicals on Adhesion. 3.1.4 Effects of Phytochemicals on the EPS Production.
Record Nr.	UNINA-9910616210203321

Pubbl/distr/stampa	Norfolk, England : , : Caister Academic Press, , [2015]
Descrizione fisica	1 online resource (346 p.)
Disciplina	616.969061
Soggetto topico	Immunotherapy Antifungal agents Biofilms
Soggetto genere / forma	Electronic books.
ISBN	1-910190-02-0
Formato	Materiale a stampa
Livello bibliografico	Monografia
Lingua di pubblicazione	eng
Nota di contenuto	Contents; Contributors; Preface; 1: Molecular Mechanisms of Resistance of Candida spp. to Membrane-targeting Antifungals; Introduction; Azoles; Non-azole ergosterol biosynthesis inhibitors; Polyenes; Concluding remarks; 2: Point Mutations and Membrane-targeting Antifungal Resistance in Aspergillus fumigatus and Other Non-Candida Species; Introduction; Aspergillus fumigatus azole resistance in clinical settings; The molecular target of azoles, allylamines and polyenes: ergosterol and ergosterol biosynthesis pathway; Differences in ergosterol pathway between Aspergillus spp. and yeasts Fungal 14-a sterol demethylases (SDMs): the main target for azole antifungalsA. fumigatus azole susceptibility patterns and mechanisms of azole resistance linked with CYP51 point mutations; Azole resistance in non-fumigatus Aspergillus; Azole secondary resistance linked with point mutations in the 14-α sterol demethylase enzyme in non-Candida and non-Aspergillus species; Polyene resistance; Resistance to allylamines; General conclusion; 3: Echinocandins: Resistance Mechanisms; Introduction; Structures; Echinocandin target: Fks1; Fks gene family; Fks1 structure-function Cell-free β-1,3-glucan synthase systemsEchinocandin uptake and efflux; Acquired echinocandin resistance: Fks hot spots 1 and 2; Differential echinocandin resistance: discovery of hot spot 3; Impact of Fks heterozygosity and redundancy on acquired resistance; Fks-independent acquired echinocandin resistance; Intrinsic echinocandin resistance: hot spot 1 substitutions; Intrinsic echinocandin resistance: hot spot 3 substitutions; Intrinsic resistance: mechanism to be determined; Stage-specific intrinsic resistance; Conclusions and future prospects; 4: Biofilms and Antifungal Resistance Introduction to fungal biofilmsFungal biofilm infections of humans; Current standard of care for fungal biofilm infections; Mechanisms of fungal biofilm drug resistance; Challenges and strategies to developing therapeutics for fungal biofilm infections; 5: Drug Combinations as a Strategy to Potentiate Existing Antifungal Agents; Introduction; In vitro and in vivo combinations with known antifungal agents; In vitro and in vivo combinations of non-antifungals with known antifungal agents; Systematic drug combination screenings Chemogenetic approaches in the exploration of drug interaction mechanismsConclusions; 6: Approaches to Detect Alternative Mechanisms of Resistance to Systemic Antifungals; Introduction; 'Omics' approaches; Mutants collections screening; Comparison with others species; Concluding remarks; 7: New Antifungal Discovery from Existing Chemical Compound Collections; Introduction; A new career for acetylsalicylic acid as an antifungal; Other non-traditional antimicrobial agents; Conclusion and future perspectives; 8: Exploring New Insights into Fungal Biology as Novel Antifungal Drug Targets Introduction
Record Nr.	UNINA-9910460916903321

Autore	Dincer Sadik
Edizione	[1st ed.]
Pubbl/distr/stampa	London : , : IntechOpen, , 2020
Descrizione fisica	1 online resource (362 pages)
Disciplina	579.17
Altri autori (Persone)	ÖzdenefeMelis Sümengen ArkutAfet
Soggetto topico	Biofilms
Formato	Materiale a stampa
Livello bibliografico	Monografia
Lingua di pubblicazione	eng
Record Nr.	UNINA-9910688451803321